Biomea Fusion, Inc. (BMEA) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Biomea Fusion, Inc. (BMEA) closed at USD 0.84 on 2026-10-15, a change of -39 % over the past year, with a market capitalization of USD 62.98M.

Biomea Fusion, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Biomea Fusion, Inc. key figures

Previous close

USD 0.84 (2026-10-15)

1-year change

-39 %

Market cap

USD 62.98M

Enterprise value

USD 29.03M

P/E ratio (trailing)

-3.00

P/E ratio (forward)

-0.92

EPS (trailing)

-0.29

EPS (forward)

-0.94

PEG ratio

n/a

Price to book

5.20

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

6.26

Employees

37

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Biomea Fusion, Inc.

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Biomea Fusion, Inc. and compare it with other stocks.